On Monday, the U.S. Food and Drug Administration in a letter (full text) to the American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine announced that during the COVID-19 emergency, it is lifting the in-person dispensing requirement for the abortion drug Mifepristone. The agency said that it was exercising enforcement discretion because of the additional COVID-related risks to patients and healthcare personnel involved in clinic visits solely to obtain the drug. It likewise will allow prescriptions for Mifepristone to be filled by mail. Washington Free Beacon reports on criticism of the FDA's move by Republican lawmakers and anti-abortion groups.
